key: cord-0733379-8grvglja
authors: So, Mitsuhito; Hifumi, Toru; Isokawa, Shutaro; Shimizu, Masato; Otani, Norio; Ishimatsu, Shinichi
title: Neuroleptic malignant syndrome in patients with COVID-19
date: 2020-05-22
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2020.05.042
sha: 9527ae87a515c82ad344f5c315d77a9c1d629458
doc_id: 733379
cord_uid: 8grvglja

We report the first two cases of Coronavirus Disease 2019 (COVID-19) who were receiving intensive care including favipiravir, and were clinically diagnosed with neuroleptic malignant syndrome (NMS) to focus attention on NMS in COVID-19 management. Case 1: A 46-year-old-man with acute respiratory distress syndrome (ARDS) caused by COVID-19 infection was being administered favipiravir. Fentanyl, propofol, and rocuronium were also given. On day 3, midazolam administration was initiated for deep sedation. On day 5, his high body temperature increased to 41.2 °C, creatine kinase level elevated, and he developed tachycardia, tachypnea, altered consciousness, and diaphoresis. NMS was suspected, and supportive therapy was initiated. High-grade fever persisted for 4 days and subsided on day 9. Case 2: A 44-year-old-man with ARDS caused by COVID-19 infection was being treated with favipiravir. On day 5, risperidone was started for delirium. On day 7, his body temperature suddenly increased to 40.8 °C, his CK level elevated, and he developed tachycardia, tachypnea, altered consciousness, and diaphoresis. NMS diagnosis was confirmed, and both, favipiravir and risperidone were discontinued on day 8. On the same day, his CK levels decreased, and his body temperature normalized on day 9. Patients with COVID-19 infection frequently require deep sedation and develop delirium; therefore, more attention should be paid to the development of NMS in patients who are being administered such causative agents. The mechanism underlying the occurrence of NMS in COVID-19 patients treated with favipiravir remains unknown. Therefore, careful consideration of NMS development is necessary in the management of COVID-19 patients.

The mortality of patients with Coronavirus Disease 2019 (COVID-19) who were receiving mechanical ventilation in Japan is considerably lower than that in the United States and European countries, possibly because of the intensive care provide in Japan that included the use of favipiravir to battle the exponential rise in the number of infections [1] [2] [3] . Favipiravir has been investigated for its efficacy against influenza [4] , and has been widely used for COVID-19 patients who were receiving mechanical ventilation in observational studies in Japan .

Patients with acute respiratory distress syndrome (ARDS) associated with COVID-19 require deep sedation, neuromuscular blockade, and steroid administration in some instances [5] , and family visits are sometimes restricted owing to the high-risk of infection spread involved in contact with COVID-19 patients [6] . Thus, patients with COVID-19 require sedatives and frequently develop delirium that is treated with the administration of major tranquilizers, such as risperidone. In such clinical situations, we treated two COVID-19

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

Effect of Flexible Family Visitation on Delirium Among Patients in the Intensive Care Unit: The ICU Visits Randomized Clinical Trial

Neuroleptic malignant syndrome

A case of neuroleptic malignant syndrome associated with midazolam administartion

Risperidone-induced neuroleptic malignant syndrome

Evaluation and Licensing Division PaFSBMoH, Labour and Welfare

Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 at

Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease

J o u r n a l P r e -p r o o f